Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Alison Tarke et al.
Summary: T cell responses induced by different vaccine platforms cross-recognize early SARS-CoV-2 variants, while memory B cells and neutralizing antibodies show significant decreases. The majority of memory T cell responses are preserved against variants, with lower recognition of Omicron by memory B cells.
Article
Microbiology
Chang Liu et al.
Summary: This study investigated several variants of SARS-CoV-2 and found that the Beta variant has the largest antigenic difference compared to other variants, such as Delta, and is poorly neutralized by serum from early pandemic and Delta viruses. The study also revealed that certain antibodies can recognize conserved neutralizing epitopes, while others target specific mutated residues in the Beta variant.
CELL HOST & MICROBE
(2022)
Article
Immunology
Matthew T. Laurie et al.
Summary: This study examines the neutralization of various SARS-CoV-2 variants and different prior exposures, such as vaccination, booster shots, and infections with different variants. The findings show that different exposures lead to varying levels of neutralization effectiveness. Stronger neutralizing antibody responses are observed against variants sharing certain spike mutations with the immunizing exposure, and exposure to multiple spike variants increases the ability to neutralize different variants. These findings contribute to our understanding of the relationship between exposures and antibody responses, and can potentially inform booster vaccination strategies.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
S. Momsen Reincke et al.
Summary: The Beta variant of concern (VOC) of SARS-CoV-2 shows resistance to neutralization by antibodies from COVID-19 patients and vaccinated individuals. Researchers have identified specific antibodies in serum from Beta-infected patients that are able to cross-react with the wild type virus. This finding provides insights into the antibody response to antigenic drift and has implications for the development of future vaccines and therapeutics.
Article
Cell Biology
Guillaume Beaudoin-Bussieres et al.
Summary: Emerging evidence suggests that both neutralizing and Fc-mediated effector functions of antibodies are important for protection against SARS-CoV-2. A non-neutralizing antibody, CV3-13, with potent Fc-mediated effector functions, was found to bind to a specific epitope of the SARS-CoV-2 spike from a unique angle. In mouse experiments, the Fc-enhanced version of CV3-13 delayed virus spread, neuroinvasion, and death, and the combination of Fc-enhanced CV3-13 with a neutralizing antibody completely protected mice from lethal SARS-CoV-2 infection.
Article
Microbiology
Allison Greaney et al.
Summary: SARS-CoV-2 variants can elicit polyclonal antibodies with different immunodominance hierarchies. The antibodies elicited by infection with B.1.351 variant are more focused on the class 3 epitope, which is mutated in the Delta variant. Prior infection and vaccination histories may partially determine individuals' susceptibilities to viral mutants in new variants.
Article
Biochemistry & Molecular Biology
Baoling Ying et al.
Summary: The study showed that current vaccination can enhance protection against Omicron infections, but different vaccines have varying efficacy, which requires further investigation.
Article
Biochemistry & Molecular Biology
Rungtiwa Nutalai et al.
Summary: This study compares the neutralization of Omicron variants of SARS-CoV-2 and finds that differences in neutralization mostly arise from variations in residues bordering the ACE2 binding site. Analysis of monoclonal antibodies isolated from vaccinated individuals shows that they can effectively neutralize early pandemic strains and exhibit broad reactivity with variants.
Article
Biochemistry & Molecular Biology
Matthew Gagne et al.
Summary: This study shows that both mRNA-1273 and mRNA-Omicron generate comparable immunity and protection after booster doses, and are able to neutralize the Omicron variant.
Article
Immunology
Yiquan Wang et al.
Summary: This study analyzed thousands of human antibodies to the SARS-CoV-2 spike protein and revealed diverse common responses. They also trained a deep-learning model using these antibody sequences, which can accurately distinguish between antibodies to different viruses.
Article
Multidisciplinary Sciences
I-Ting Teng et al.
Article
Cell Biology
Lihong Liu et al.
Summary: This study identified a human monoclonal antibody, 10-40, that can neutralize or bind all tested sarbecoviruses and provide protection against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies showed that 10-40 has the broadest effectiveness against sarbecoviruses among other receptor-binding domain (RBD)-directed antibodies, making it a promising candidate for pandemic preparedness. Structural analyses also revealed a conserved epitope cluster and a distinct antibody class with a common CDRH3 motif.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Omicron sublineages BA.2.12.1, BA.4 and BA.5 have higher transmissibility and increased evasion of neutralizing antibodies compared to the BA.2 lineage. They exhibit similar binding affinities to the ACE2 receptor as BA.2. BA.1 infection after vaccination boosts humoral immune memory against wild-type SARS-CoV-2, but these antibodies are largely evaded by BA.2 and BA.4/BA.5 variants.
Article
Medicine, General & Internal
Heba N. Altarawneh et al.
Summary: An analysis of data from Qatar showed that previous infection, vaccination, and hybrid immunity all demonstrated effectiveness in protecting against symptomatic Covid-19 caused by the BA.1 and BA.2 sublineages of the Omicron variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Microbiology
Allison J. Greaney et al.
Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Gabriele Cerutti et al.
Summary: Structural analysis revealed that seven potent NTD-directed neutralizing antibodies target a common surface on NTD, forming a single supersite different from the recognition pattern of RBD-directed antibodies.
CELL HOST & MICROBE
(2021)
Article
Immunology
Vincent Dussupt et al.
Summary: Multiple monoclonal antibodies targeting the RBD or NTD of the SARS-CoV-2 spike protein have potent cross-neutralizing activities against variants of concern, and when used in combination, they have complementary effects on viral neutralization and can protect against viral escape mutants.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Summary: The study found that neutralizing antibody responses against several variants of concern gradually declined after vaccination with the mRNA-1273 vaccine for the SARS-CoV-2 virus. However, boosting nonhuman primates with either homologous or heterologous mRNA-1273 vaccines after 6 months resulted in increased neutralizing antibody responses across all variants of concern, which lasted for at least 8 weeks after the boost. After being challenged with the SARS-CoV-2 Beta variant 9 weeks post-boost, viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, indicating the potential necessity for booster vaccinations to maintain immunity and protection.
Article
Biochemical Research Methods
Sarah A. Robinson et al.
PLoS Computational Biology
(2021)
Article
Multidisciplinary Sciences
Ge Song et al.
Summary: This study examines the impact of pre-existing immunity to seasonal endemic coronaviruses on antibody responses to SARS-CoV-2, finding weak evidence of pre-existing cross-reactive serum antibodies in pre-pandemic donors, but evidence of pre-existing cross-reactive memory B cells activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, and one neutralizing antibody specific to the S2 subunit of the S protein is identified, suggesting that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Micah Rapp et al.
Summary: Antibodies derived from the VH1-2 gene have been shown to be potent neutralizing antibodies against SARS-CoV-2, with three VH1-2-derived antibodies (2-15, 2-43, and H4) using VH1-2-encoded motifs to recognize the receptor-binding domain (RBD) of the virus spike protein. Despite genetic similarities, these antibodies are able to recognize both up and down conformations of the RBD, with some antibodies using elongated CDRH3s to interact with glycan N343 on a neighboring RBD. The VH1-2 antibody class utilizes modular genetic elements for modular recognition, with VH gene specifying RBD recognition and CDRH3 specifying quaternary interactions.
Article
Biochemistry & Molecular Biology
Dapeng Li et al.
Summary: Research has shown that some SARS-CoV-2 neutralizing antibodies can enhance virus infection in vitro, but in monkeys and mice, these antibodies can still protect against SARS-CoV-2. However, out of 46 monkeys infused with enhancing antibodies, three showed higher lung inflammation scores compared to controls.
Article
Biochemistry & Molecular Biology
Yuhan Hao et al.
Summary: The study introduces a weighted-nearest neighbor analysis framework to learn the relative utility of each data type in each cell, enabling integrative analysis of multiple modalities. Applied to a CITE-seq dataset, the method constructs a multimodal reference atlas of the circulating immune system and successfully identifies and validates previously unreported lymphoid subpopulations.
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Article
Biochemistry & Molecular Biology
Pei Tong et al.
Summary: Memory B cell reserves can produce protective antibodies against SARS-CoV-2, but the impact on variants is unclear. Studying antibodies from convalescent individuals revealed seven major antibody competition groups, important for neutralizing the virus.
Article
Multidisciplinary Sciences
Fabian Schmidt et al.
Summary: The number and variability of neutralizing epitopes targeted by polyclonal antibodies in individuals who have recovered from SARS-CoV-2 or been vaccinated play a crucial role in determining the breadth of neutralization and the genetic barrier to viral escape. Studying HIV-1 pseudotypes and plasma selection experiments, it was found that human polyclonal antibodies target multiple neutralizing epitopes within and outside the receptor-binding domain, and antibody targets coincide with spike sequences enriched for diversity in natural SARS-CoV-2 populations. Combining plasma-selected spike substitutions led to the generation of 'polymutant' spike protein pseudotypes that resist neutralization by polyclonal antibodies to a similar extent as circulating variants of concern. Plasma from individuals who had been infected with SARS-CoV-2 and subsequently received mRNA vaccination was able to neutralize highly resistant SARS-CoV-2 variants, suggesting that optimally elicited polyclonal antibodies can provide protection against future SARS-CoV-2 variations and potential sarbecovirus pandemics.
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Biochemistry & Molecular Biology
Yunlong Cao et al.
Article
Immunology
Emilie Seydoux et al.
Article
Multidisciplinary Sciences
Davide F. Robbiani et al.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Article
Biochemistry & Molecular Biology
Seth J. Zost et al.
Article
Multidisciplinary Sciences
Philip J. M. Brouwer et al.
Article
Multidisciplinary Sciences
Anna Z. Wec et al.
Article
Cell Biology
Tongqing Zhou et al.
Article
Biology
Yiska Weisblum et al.
Article
Immunology
Shelly J. Krebs et al.
Article
Multidisciplinary Sciences
Cinque Soto et al.
Article
Genetics & Heredity
Amit A. Upadhyay et al.
Article
Immunology
Chaim A. Schramm et al.
FRONTIERS IN IMMUNOLOGY
(2016)
Article
Biochemistry & Molecular Biology
Marie-Paule Lefranc et al.
NUCLEIC ACIDS RESEARCH
(2015)
Article
Biochemical Research Methods
Robert C. Edgar
